{
    "clinical_study": {
        "@rank": "1505", 
        "arm_group": [
            {
                "arm_group_label": "1-year treatment with icotinib", 
                "arm_group_type": "Experimental", 
                "description": "Patients will receive 1-year treatment with icotinib after operation."
            }, 
            {
                "arm_group_label": "2-year treatment with icotinib", 
                "arm_group_type": "Experimental", 
                "description": "Patients will receive 2-year treatment with icotinib after operation."
            }
        ], 
        "brief_summary": {
            "textblock": "Adjuvant therapy has been proved effective in treating stage II-IIIA non-small-cell lung\n      cancer. This study is designed to evaluate the efficacy of icotinib as adjuvant therapy in\n      treating such patients. The primary endpoint is to compare the recurrence-free survival\n      after 1-year or 2-year treatment with icotinib."
        }, 
        "brief_title": "Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR Mutation", 
        "completion_date": {
            "#text": "August 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-small-cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The patients signed the written informed consent\n\n          -  The patients present with operable stage II-IIIA non-small-cell lung cancers with 19\n             or 21 exon mutation\n\n          -  The patients have no history of anti-cancer therapies including chemotherapy,\n             radiation therapy\n\n          -  The patients' Eastern Cooperative Oncology Group scores are \u2264 0-2\n\n        Exclusion Criteria:\n\n          -  Patients with unresected tumor\n\n          -  Wild EGFR type\n\n          -  Allergic to the study drug\n\n          -  Patients have severe non-cancerous diseases\n\n          -  Patients are undergoing current administration of anti-cancer therapies, or are\n             attending some other clinical trials"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01929200", 
            "org_study_id": "BD-IC-IV50"
        }, 
        "intervention": [
            {
                "arm_group_label": "1-year treatment with icotinib", 
                "description": "Icotinib is administered orally with a dose 125 mg 3 times daily within 4-6 weeks after operation for 1 year.", 
                "intervention_name": "1-year treatment with icotinib", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Commana", 
                    "BPI-2009"
                ]
            }, 
            {
                "arm_group_label": "2-year treatment with icotinib", 
                "description": "Icotinib is administered orally with a dose 125 mg 3 times daily within 4-6 weeks after operation for 2 years.", 
                "intervention_name": "2-year treatment with icotinib", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Commana", 
                    "BPI-2009"
                ]
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 11, 2014", 
        "location": {
            "contact": {
                "email": "zlyangyue@bjmu.edu.cn", 
                "last_name": "Yue Yang, MD", 
                "phone": "86-10-88196568"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "zip": "100142"
                }, 
                "name": "Beijing Cancer hospital"
            }, 
            "investigator": {
                "last_name": "Yue Yang, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized, Open-label, Multicenter Study of Icotinib as Adjuvant Therapy in Treating Stage II-IIIA Non-small-cell Lung Cancer Patients With Positive EGFR Mutation", 
        "overall_contact": {
            "email": "zlyangyue@bjmu.edu.cn", 
            "last_name": "Yue Yang, MD", 
            "phone": "86-10-88196568"
        }, 
        "overall_official": {
            "affiliation": "Beijing Cancer Hospital", 
            "last_name": "Yue Yang, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Recurrence-free Survival", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "reference": {
            "PMID": "23621919", 
            "citation": "Lv C, Ma Y, Feng Q, Fang F, Bai H, Zhao B, Yan S, Wu N, Zheng Q, Li S, Chen J, Wang J, Feng Y, Wang Y, Pei Y, Fang J, Yang Y. A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma. World J Surg Oncol. 2013 Apr 26;11:96. doi: 10.1186/1477-7819-11-96."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01929200"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Overall survival", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "source": "Betta Pharmaceuticals Co.,Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Betta Pharmaceuticals Co.,Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}